Your session is about to expire
← Back to Search
Ra-223 for Prostate Cancer
Study Summary
This trial studies if using PSMA PET scans to select patients for Ra-223 radiation therapy is effective in treating prostate cancer that has spread to bones.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is only in the bones, confirmed by a special PET scan.I am a man aged 18 or older.I can take care of myself and am up and about more than half of my waking hours.My cancer progressed despite treatment with drugs like abiraterone.My prostate cancer is getting worse according to specific criteria.I have undergone at least two cycles of chemotherapy that included a taxane.I am eligible for Ra-223 cancer treatment.My testosterone levels are very low, as confirmed by a recent test.My side effects from previous cancer treatments are mild.My cancer has spread to my organs or brain/spine and hasn't been treated there.I have previously been treated with specific radioactive medications.I have not had a blood transfusion in the last 45 days.I have previously undergone radioligand therapy.I have another cancer type, but it won't affect this trial's treatment.I haven't had any cancer treatments like chemotherapy or immunotherapy in the last 3 weeks.Over 75% of my bones are affected, as shown by a PSMA PET scan.My cancer has spread to lymph nodes, but they are small and haven't grown in 6 months.
- Group 1: Treatment (NaF PET/CT/MDP, Ra-223, PSMA PET)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned NaF PET/CT/MDP, Ra-223, and PSMA PET for therapeutic purposes?
"Our experts at Power have determined the safety of Treatment (NaF PET/CT/MDP, Ra-223, PSMA PET) to be a 2 on a scale from 1 to 3 due to its Phase 2 status. This indicates that while there is evidence supporting its security, efficacy has yet to be documented."
Is this medical research currently accessible to participants?
"As reported on clinicaltrials.gov, this particular medical study is no longer recruiting subjects. The trial was first announced on August 1st 2023 and the most recent update occurred on June 20th of that year. There are however 3709 other studies actively searching for patients at present time."
Share this study with friends
Copy Link
Messenger